Business, energy, technology, markets and global industry news from Business News Today

psychedelic therapeutics

PharmaDeviceNews psychedelic therapeutics
Pharma & Biotech

How Clearmind Medicine is positioning CMND-100 within the emerging non-hallucinogenic neuroplastogen market

Clearmind Medicine is advancing CMND-100 in Alcohol Use Disorder. Discover why the non-hallucinogenic neuroplastogen market is gaining attention.

Read More
Features & Analysis

How the PharmAla Biotech Holdings Inc. and Jupiter Neurosciences, Inc. deal reflects changing investor expectations in psychedelics

Explore why the PharmAla and Jupiter Neurosciences licensing deal could reshape investor sentiment around next-generation psychedelic therapeutics.

Read More
Pharma & Biotech

Why Psyence Biomedical Ltd.’s Australian trial strategy could shape global psychedelic drug development pathways

Psyence Biomedical Ltd. advances NPX-5 dosing in Australia. Discover how this trial strategy could shape global psychedelic drug development.

Read More
Pharma & Biotech

How subcutaneous amivantamab approval in Europe could reshape EGFR-mutated NSCLC treatment workflows

EU approves subcutaneous amivantamab for expanded EGFR lung cancer dosing. Discover what this changes for clinicians and health systems.

Read More
Pharma & Biotech

Can PharmAla’s three year stability program de risk MDMA distribution challenges?

PharmAla will generate three year stability data for LaNeo MDMA. Discover how this could shape packaging, regulation, and commercialization.

Read More
Pharma & Biotech

Why Compass Pathways’ upcoming COMP360 data could redefine late-stage psychedelic drug development

Compass Pathways is set to release pivotal Phase 3 COMP360 data in treatment-resistant depression. Find out why this readout could reshape psychedelic drug development.

Read More